Blood Podcast

This week's episode will review efforts to improve the activity of CAR T cells, explore the impact of Protein C activator AB002 on thrombus development, and look at results from a UK study on minimal residual disease status and outcome after transplantation in NPM1-mutated AML.

This week’s episode will examine how graft versus host disease in the colon is driven by an inflammatory cytokine produced by specialized donor T cells, review a prospective, multicenter study to assess the frequency and clinical relevance of low level mutations in chronic myeloid leukemia, and learn about a potential new therapeutic that blocks the activity of the iron-regulatory hormone Erythroferrone to reduce iron overload in thalassemia.

This week’s episode will review treatment for secondary prevention of venous thromboembolism in children, a therapeutic strategy for relapsed or refractory B-cell acute lymphoblastic leukemia, Ivosidenib monotherapy in patients with newly diagnosed AML with mutations in the isocitrate dehydrogenase 1 gene, and survival outcomes of chronic Lymphocytic Leukemia patients treated with Ibrutinib.

This week’s episode will examine the critical role of platelet necrosis in ischemic stroke injury, the discovery of the molecular basis for the PEL blood group, and the impact of NPM1/FLT3-ITD genotypes in patients with acute myeloid leukemia.

In this episode we welcome Drs. Thomas Ortel, Jeffrey Weitz, and Kenneth Bauer as they discuss the Blood Review Series on the Treatment of Venous Thrombotic Disorders. In this review series, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.Review Series on Treatment of Venous Thrombotic Disorders

Discover groundbreaking advancements in CAR T-cell therapy enhancing remission durability for pediatric leukemia. Delve into the genomic factors linked to breast implant-associated lymphomas. Learn about alarming new findings that connect arterial thrombotic events in patients with myeloproliferative neoplasms to an increased risk of developing a second cancer. This insightful discussion highlights the latest in cancer treatment and risk assessments.

Delve into the fascinating world of genetics as the discussion unfolds on heredity versus environment in age-related clonal hematopoiesis. Discover groundbreaking insights into mutations of the thrombopoietin receptor and their implications for myeloproliferative neoplasms. The role of complement activation is also highlighted, especially relating to thrombotic disorders. This engaging exploration sheds light on the urgent need for enhanced diagnostics and therapeutic strategies in hematologic conditions.

Exploring breakthroughs in treating T-cell acute lymphoblastic leukemia, the discussion highlights intensified pediatric protocols and innovative therapies, including case studies showcasing successful outcomes. It also delves into the use of a thrombopoietin agonist to address thrombocytopenia after stem cell transplants. Furthermore, the talk reveals exciting advances in microRNA-146a for targeted treatments, emphasizing its potential antitumor effects, especially in patients receiving CAR T-cell therapy.

This episode will explore the consequences of a loss of the interaction between mutant calreticulin and another ER resident protein, and how this may promote myeloproliferative neoplasms, the role of a calcium-induced transcription factor in driving diffuse large B-cell lymphoma signaling, and a comparison of two therapies for standard risk acute graft-versus-host disease.

This episode will highlight a unique treatment for refractory hematologic malignancies, therapy-induced mutations impacting the genomic landscape of relapsed acute lymphoblastic leukemia, and a unique approach to avoiding chronic graft-versus-host disease.